Cue Biopharma, Inc. has reported a recent transaction involving its Chief Legal Compliance Officer, Ray Sumita, who sold shares of the company's stock. This event highlights the company's adherence to internal policies regarding stock transactions and tax obligations.
Background
Cue Biopharma, Inc., classified under the SIC code 2834 for Pharmaceutical Preparations, operates as an innovative biopharmaceutical company. The firm is listed on the Nasdaq under the ticker symbol CUE. It focuses on developing therapies that leverage the immune system to treat diseases. The company has been active in filing various forms with the SEC, including recent filings on October 14, 2026, which include multiple Form 4 submissions.
What the Filing Says
According to the recent SEC filing (accession number 0001579629-26-000012), Ray Sumita sold 1,844 shares of Cue Biopharma common stock on October 12, 2026, at a price of $28.05 per share. The filing notes, "The sales reported represent shares sold pursuant to the Issuer's Company-Wide Policy and do not represent discretionary transactions by the Reporting Person." This transaction was executed to satisfy mandatory tax withholding obligations through a "sell-to-cover" mechanism related to the vesting of restricted stock units.
Impact
This transaction may affect stakeholders, including employees and investors, as it reflects the company's structured approach to stock management and compliance with tax obligations. The filing indicates that Sumita retains 116,701 shares following the transaction, suggesting continued confidence in the company's future.
What's Next
The filing does not say what happens next.